Telehealth & GLP-1 access: how patients get the drugs

One thing made the GLP-1 boom unusual: a great deal of it happened outside the traditional doctor-and-pharmacy path. People sought these drugs through apps, paid cash when insurance would not cover them, and — during official shortages — obtained compounded copies. That created fast-growing businesses in the telehealth weight loss space, and also the most volatile, regulation-exposed link in the whole chain.

Where this sits in the ripple

Duopoly · Pill · Factory · Delivery · Access · Consumer ripple · Healthcare ripple · Forces

The access layer connects the makers to patients. Links up to The Boom. It is the GLP-1 cousin of the distribution-and-pharmacy middlemen link in our Healthcare series.

What this link is

• Compounding. When a drug is in official shortage, certain pharmacies are permitted to make copies. A wave of compounded GLP-1s filled the gap during shortages — until regulators declared the shortage resolved, winding much of that activity down and reshaping the businesses built on it.
• Direct-to-consumer pharmacy. The makers launched their own cash-pay channels to sell directly to patients, bypassing parts of the traditional system.
• Why this link is fragile. Its economics can change with a single regulatory decision — which is the defining risk below.

The companies

Note: the main telehealth names here are smaller, non-index companies; we profile them lightly and flag that. CVS is the large, established access route.

Hims & Hers (HIMS)

What they do: a direct-to-consumer telehealth platform that grew rapidly offering weight-management programmes, including compounded GLP-1s during the shortage. The numbers:. The edge: a strong consumer brand and a direct relationship with patients. The risk: the model is acutely sensitive to regulation and to the makers' own direct channels — the end of compounding access struck at a core offering. (Treat as a non-index, higher-risk name; verify status at draft.)

LifeMD (LFMD)

What they do: a smaller telehealth prescriber operating in the same direct-to-consumer space. The numbers:. The edge: a foothold in fast-growing online care. The risk: limited scale and the same heavy dependence on a shifting regulatory backdrop.

CVS Health (CVS)

What they do: the large, listed pharmacy-and-insurer that represents the "establishment" access route — retail pharmacy, plus the formulary decisions that determine coverage (cross-link to the payers and middlemen links). The numbers:. The edge: scale and an integrated position across pharmacy, insurance, and pharmacy-benefit management. The risk: as a payer-adjacent gatekeeper, its coverage and formulary choices cut both ways — and GLP-1 costs pressure its own margins.

The bull and bear case

The bull case: direct access widened the market quickly and built genuine consumer brands in healthcare — a structural shift toward how people buy care.

The bear case: this is the lowest-moat, most regulation-exposed link in the chain. A rule change can reshape an entire business model overnight, as the compounding wind-down showed.

What feeds it, what it feeds

The access layer is fed by The Delivery and connects the makers to patients. That completes the inner rings — from molecule to medicine cabinet. Now the ripples spread outward. Next, the consumer economy: The Consumer Ripple. Back to the map: The Boom.

This article is for information only. It is not medical advice and not investment advice or a recommendation to buy or sell any security. TradeRadarNews is not a licensed financial or medical adviser. Figures are accurate as of June 2026 and will change. Markets carry risk, including loss of capital. Rules, taxes, and available products differ by country — do your own research and consult a locally regulated professional.